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treated cells, a number of differentially expressed transcripts were identified and cloned. 
Sequence homology search revealed and matched the identified clones to 1) a small 
subset of genes known to be involved in angiogenesis, e.g. platelet endothelial cell adhe- 
sion molecule 1 (PECAM-I), matrix metalloproteinase 2 (MMP2), endothelin converting 
enzyme 1 (ECE-I), and vascular endothelial growth factor receptor 2 (VEGFR-2); 2) a 
large subset of known genes with known function, but not involved in angiogenesis to 
date; and 3) about 5-10% of the clones were novel genes with unknown function, such as 
a putative G-protein coupled receptor. Thus there are clusters of related gene products, 
differentially regulated and involved with cholinergic, proliferative and apoptotic action. 
cDNA rmcroarray analysis (-48,000 elements) validated our findings Conclwon: Nico- 
tme promotes angiogenesis through stimulation of angiogenic mechanisms partly 
through the cholinerglc pathway. Therapeutic modulation of nAChR may be useful in dls- 
orders of angiogenesis. 
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Background: Hyperhomocyst(e)inemia has been implicated in atherosclerws and can 
be determined by multiple environmental and genetlc factors. However, the relationship 
of the plasma levels of homocyst(e)ine (Ho) and folate (F) with the C?“T methylentet- 
rahydrofolate reductase (MTHFR) gene polymorphism and coronary artery disease 
(CAD) has never been investigated in a large clinlcal dataset. Methods: In 964 consecu- 
tive patients (63iiO yrs. 74% men and 26% women) of the “GENICA” study, who under- 
went coronary anglography for suspected CAD, we measured HO and F by HPLC and a 
chemilummescence method, respectively. All were genotyped for the d”T MTHFR 
gene polymorphism by fluorescent PCR and melting curve analysis (LightCycls+). 
ResuI1s: We found a highly significant (p<O.OOOl) inverse relationship between Ho and 
F. A multivariate analysis identified serum creatinine, Cs”T MTHFR genotypes, F, left 
ventncular election fraction, age, and an interaction between Cs7’T MTHFR genotypes 
and F, as significant predictors of Ho (Re0.16, p<O.OOOl). When the effect of the T 
MTHFR allele was examined according to a recessive model, significantly (pcO.0001) 
higher Ho values were seen in TT (14.9eO.6 Mmol/l) than in CC+CT (12.0r0.3 pmolll) 
patients. At variance no signlflcant difference was seen between patients with (14.0r0.6 
umol/l) and wthout CAD (I 3.OtO.4 ~molll). x2 analysis showed that high Ho (z-15 pmol/l) 
were more common than expected in patients with history of previous myocardial infarc- 
tion (p=O.O03), peripheral vascular disease (p<O.OOl), vascular surgery (p<O.OOl) and 
chronic renal failure (p<O.OOl). No associations of the C?“T MTHFR polymorphism with 
such outcomes were seen. Conclusions: These results, in patients with angiographl- 
tally-assessed CAD, support the contentlon of Ho being determined by multiple factors, 
including the Cs”T transItion in the MTHFR gene. Furthermore, they indicate that hyper- 
homocyst(e)inemia. but not the C?“T MTHFR alleles, are associated with cardiovascu- 
lar outcomes albeit not with anglographically assessed CAD. 
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804-4 Endothelin-1 Induces Expression of Functional CD40 on 
Human Vascular Smooth Muscle Cells 
Michael Browatzki. Caroline A. Pfeiffer, Roger Kranzhbfer, University of Heidelberg, 
Heidelberg, Germany 
Background: Chronic inflammation of the vessel wall IS a hallmark of atherosclerosis. 
This inflammatory process is maintalned by a variety of cytokines generated in the vessel 
wall. Recently, activatmn of vascular cells by cell-cell contact via the CD40lCDl54 sys- 
tem has been identified as Important pathway of inflammatory stimulation in atherogene- 
sis. Human vascular smooth muscle cells @MC) as important cellular component of the 
atherosclerotic plaque can express both cytokines and the CD40/CDl54 system. On the 
other hand, the vasoactve peptide endothelin-1 (ET-l) is supposed to contribute to 
atherogenesis. This study investigated whether ET-l stimulates the inflammatory 
response in SMC via a CD40/CD154 dependent pathway. Methods and Results: ET-l 
(10 nM max) like the positive stimulus interieron-gamma (100 U/ml) increased CD40 
mRNA and protein expression after 24 hours in human SMC. This ET-l effect was medi- 
ated by the ET-A-receptor subtype since BQ-123, a selective ET-A receptor antagonist, 
prevented ET-l-induced CD40 upregulatlon whereas BQ-788. an ET-B-receptor antago- 
nist, did not (10 pM each). ET-l also activated the proinflammatory transcription factors 
NF-kappaB and AP-1 in a time dependent manner. The specific proteasome inhibitor PI- 
1 (50 PM) and a NF-kappaB decoy oligodesoxynucleotide prevented ET-l-induced CD40 
expression demonstrating dependence of this ET-1 effect on NF-kappa6 activation To 
test the functional relevance of the CD40 expression, SMC were premcubated with IO 
nM ET-1 for 24 hours and afterwards stimulated with recombinant CD154 (5 ng(ml). 
Release of Interleukin-6 (IL-6) into the culture medium was assessed by ELISA. Cells 
preincubated with ET-1 secreted a slgniflcantly higher amount of IL-6 under CD154 stim- 
ulation than control cells (265 +/- 4 vs 147 +/- 8 pglml, p < 0.05). Conclwon: ET-l 
induces an inflammatory response I” human SMC wa direct cell-cell contact which is 
medlated by the CD40ICD154 system. This mechanism may contribute to the pathogen- 
esis of atherosclerosis. 
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Background: Proliferation of vascular smooth muscle cells (VSMC) is involved in the 
pathogenws of primary atherosclerosis and restenosis after angioplasty. On the back- 
ground of the recently proposed antiproliferative actiwties of caveolm1 the present study 
investigated the expression of caveolin- in proliferating VSMC in vitro and especially in 
human atheroma. 
Methods and Results: Primary VSMC express high levels of caveolin- as shown by 
immunoblotting. Supplementation of serum or growth factors such as PDGF caused a 
decrease in caveolin- expressjon in VSMC. Cell-cycle entry was documented by a 
decrease of the Cdk inhibitor p27kipl and an increase of the proliferating cell nuclear 
antigen (PCNA). We further investigated the expression of caveolin- in VSMC of human 
atheroma using immunohistochem&y. In contrast to control vessels, caveolin- was 
markedly decreased in sections derived from human atheroma. The proliferation of 
VSMC m atheroma was confirmed by an increased PCNA immunostaining. 
Conclusion:Thls newly characterized decreased expression of caveolin- both in prolif- 
erating smooth muscle cells in vitro and in human atheroma in viva strongly links the loss 
of the antiproliferative control by caveolin- to the development of atherosclerosis, sug- 
gesting a pivotal role of caveolin- in the pathogenesis of atherosclerosis. 
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811-1 Pulmonary Artery Systolic Pressure in 
Echocardiographically Normal Subjects 
Richard V Milani, Carl J. Lavie, Yvonne E. Gilliland. Krishnamoorthy Vivekananthan. 
Mark M. Cassidy, Jose Albert0 Bernal, Ali Morshedl, Ochsner Clinic Foundation, New 
Orleans, LA 
Backgrond: Pulmonary hypertension (PHTN) has undergone renewed interest of late 
with the increasing prevalence of obesity and the reported association of various anorec- 
tic agents and its subsequent effect on the pulmonary vasculature. Recent enhance- 
ments I” echocardiographic instrumentation, has refined the detection of small degrees 
of tricuspid regurgitation in subjects, and mild “elevations” of pulmonary artery systolic 
pressure (PASP) are now a common finding, resulting in concern as to whether this rep- 
resents true pathology. Previous definitions of PHTN suggested that PASP exceeding 30 
mmHg were pathologic, however this data was often derived from small numbers of rela- 
tively young patients. 
Methods: We have analyzed PASP from our echocardiographic database of 35,815 sub- 
jects, resulting in 2,472 subjects (mean age 54.9 +I- 16.3 years) which met the echo cri- 
teria of normal hearts, defined as: normal left and right ventricular dimension and 
function; normal left and right atrial dimensions; absence of aortic root dilatation or peri- 
cardial disease; absence of valvular stenosis; absence of valvular insufficiency less than 
moderate. 
Results: The mean PASP was 33.1 +/- 7.7 mmHg, and correlations were found wth age 
(p=O.OOOl), male gender (p=O.O025), septal wall thickness (p=O.OOOl) and posterior wall 
thickness (p=O.OOOl). 60% of this population had a PASP > BOmmHg, and 22% of those 
older than 50 years, and 20% of those with BMI > 30 kgIm2, had a PASP > 40mmHg. 
Conclusions: Elevations of PASP is relatively common in echocardiographically normal 
populations and correlate to age and BMI. Previous definitions of normal PASP should 
be revised to adjust for age. 
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811-2 Inhibition of Phosphodiesterased and Nitric Oxide 
Similarly Reduce Pulmonary Artery Pressure at High 
Altitude 
Hans P. Brunner-La Rocca Patrick Egger, Oliver Senn, Manuel Ftschler, Rahel 
Thalmann, Konrad Bloch, Marco Magglorini, Unwersity Hospital, Zurich, Switzerland, 
Uwersity Hospital, Basel, Switzerland 
Background At high altitude, hypoxia induces pulmonary hypertension which plays an 
Important role in the pathophysiology of high-altitude pulmonary edema. Inhaled nitric 
oxide (NO) was shown to reduce pulmonary artery pressure (PAP), but it is not applica- 
ble in parctlce. Therefore, we investigated the effects of the PDEB-Inhibitor sildenafil (Sil) 
on PAP at high altitude in comparison with Inhaled NO. 
Methods Doppler-echocardiography was performed in 22 healthy mountaineers (10 W, 
12 M, age 29*12y; Q-saturation 75*3%) 3 hours after they reached an altitude of 
4559m. Measurements were repeated after NO (40ppm), Sil (50mg), and Sil plus NO. 
PAP was estimated from trtcuspid regurgitation and pulmonary vascular resistance 
